Why the study?
Cardiovascular toxicities adversely affect cancer outcomes, but decentralized evaluations and isolated studies have led to a lack of consensus on optimal cardiovascular imaging uses in contemporary cancer treatment.
This AHA scientific statement provides consensus guidance on the optimal application of multimodality cardiovascular imaging for the detection, monitoring, and management of cardiotoxicity in patients receiving contemporary cancer therapies.
No takes yet. Share an insight, caveat, or question.
Supports imaging integration in cardio-oncology protocols; leaves open prospective validation of strategies in cancer survivors.
Addison et al. (2023) studied this question. Cardiovascular imaging is essential for detecting and managing cardiac risks in nearly 20 million cancer patients undergoing advanced therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: